TP53 and acute myeloid leukemia: Given the selectivity inhibition of class I HDACs particularly HDAC3, and p53 activation by IHCH9033, along with its superior pharmacological properties, further investigation into its effects on AML LSCs is warranted, with future studies set to explore its activity both alone and in combination with quizartinib in this patient population.